- subacute cutaneous lupus erythematosus
- relating to or existing on or affecting the skin; "cutaneous nerves"; "a cutaneous infection" (同)cutaneal, dermal
- any of several forms of ulcerative skin disease
- a constellation in the southern hemisphere near Centaurus
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
- [Current therapeutic indications of thalidomide and lenalidomide.]
- Ordi-Ros J1, Cosiglio FJ2.Author information 1Servicio de Medicina Interna, Hospital Vall d'Hebron, Instituto de Investigación Vall d'Hebron, Universidad Autónoma de Barcelona, Barcelona, España. Electronic address: Jordi@vhebron.net.2Servicio de Clínica Médica, Hospital Provincial del Centenario, Facultad de Ciencias Médicas, Universidad Nacional de Rosario, Rosario, Argentina.AbstractThalidomide is a synthetic glutamic acid derivative first introduced in 1956 in Germany as an over the counter medications. It was thought to be one of the safest sedatives ever produced as it was effective in small doses, was not addictive, and did not have acute side-effects such as motor impairment, but was quickly removed from market after it was linked to cases of severe birth defects. The Food and Drug Administration approved use in the treatment of erythema nodosum leprosum. Further, it was shown its effectiveness in unresponsive dermatological conditions such as actinic prurigo, adult Langerhans cell hystiocytosis, aphthous stomatitis, Behçet syndrome, graft-versus-host disease, cutaneous sarcoidosis, erythema multiforme, Jessner-Kanof lymphocytic infiltration of the skin, Kaposi sarcoma, lichen planus, lupus erythematosus, melanoma, prurigo nodularis, pyoderma gangrenosum and others. In May 2006, it was approved for the treating multiple myeloma. New thalidomide analogues have been developed but lack clinical experience. This paper is a review of the history, pharmacology, mechanism of action, clinical applications and side effects of thalidomide and its analogues.
- Medicina clinica.Med Clin (Barc).2014 Apr 22;142(8):360-364. doi: 10.1016/j.medcli.2013.04.038. Epub 2013 Jul 3.
- Thalidomide is a synthetic glutamic acid derivative first introduced in 1956 in Germany as an over the counter medications. It was thought to be one of the safest sedatives ever produced as it was effective in small doses, was not addictive, and did not have acute side-effects such as motor impairme
- PMID 23830554
- Differential management of mild-to-severe psoriasis with biologic drugs: An Italian Delphi consensus expert panel.
- Girolomoni G1, Altomare G, Ayala F, Berardesca E, Calzavara Pinton P, Chimenti S, Martini P, Peserico A, Puglisi Guerra A, Antonio Vena G; on behalf on the Delphi working group.Author information 1Department of Medicine, Section of Dermatology and Venereology, University of Verona , Verona , Italy .AbstractAbstract Background: In the management of moderate-to-severe psoriasis, increasingly complex clinical scenarios necessitate practical tools for appropriate biologic therapy selection in individual patients. An Italian Delphi consensus panel provided guidance on biologic use in selected clinical scenarios. Methods: Ten experts defined statements under consideration, which were distributed as an online survey to a dermatologist panel. Plenary discussions of contentious statements were held to achieve consensus. Results: The survey was sent to 30 clinicians. After plenary discussions, consensus was reached on all 20 statements on the following topics: special populations; infections; comorbidities; immunogenicity; extra-cutaneous involvement; pregnancy; and adherence. Three statements required further discussion in order to gain consensus: use of subcutaneous biologics in mild liver impairment (final 94% agreement), use of any biologic in discoid lupus erythematosus (final 100% disagreement), and use of etanercept in patients with history of hypersensitivity reactions to drugs and/or food (final 75% disagreement). Conclusions: This Delphi expert consensus on the use of biologics in psoriasis provides practical recommendations for dermatologists to use when choosing an appropriate biologic in challenging but common clinical scenarios. More data are required to clarify clinical differences of biologic drugs used to treat psoriasis.
- The Journal of dermatological treatment.J Dermatolog Treat.2014 Apr 8. [Epub ahead of print]
- Abstract Background: In the management of moderate-to-severe psoriasis, increasingly complex clinical scenarios necessitate practical tools for appropriate biologic therapy selection in individual patients. An Italian Delphi consensus panel provided guidance on biologic use in selected clinical scen
- PMID 24708158
- Cutaneous horn arising from an area of discoid lupus erythematosus on the scalp.
- Fatani MI1, Hussain WM, Baltow B, Alsharif S.Author information 1Department of Medicine, Hera General Hospital, Makkah, Saudi Arabia.AbstractA cutaneous horn is a rare clinical condition characterised by a conical projection of hyperkeratotic epidermis. Cutaneous horns most commonly arise from sun-exposed skin in elderly men, but may arise from any part of the body at any age in men and women. When a cutaneous horn forms, it is important to determine the underlying cause. Various skin diseases may present with cutaneous horns including viral warts, actinic keratosis, keratoacanthoma, seborrhoeic keratosis, pyogenic granuloma, discoid lupus erythematosus, verruca vulgaris, Bowen's disease, basal cell carcinoma and squamous cell carcinoma. The underlying pathology is benign in 61.1% of cases, premalignant in 23.2% of cases and malignant in 15.7% of cases. We report a patient with a cutaneous horn arising from an area of discoid lupus erythematosus on the scalp.
- BMJ case reports.BMJ Case Rep.2014 Apr 3;2014. pii: bcr2013202322. doi: 10.1136/bcr-2013-202322.
- A cutaneous horn is a rare clinical condition characterised by a conical projection of hyperkeratotic epidermis. Cutaneous horns most commonly arise from sun-exposed skin in elderly men, but may arise from any part of the body at any age in men and women. When a cutaneous horn forms, it is important
- PMID 24700037
- 著明な色素沈着を伴いBlaschko線に沿ってみられたLinear Cutaneous Lupus Erythematosusの1例 (特集 膠原病)
- 全身性エリテマトーデス患者の四肢に生じた皮膚Mycobacterium intracellulare感染症の1例 (特集 細菌・抗酸菌感染症)
- Cutaneous lupus erythematosus. Authoritative facts about the skin from DermNet New Zealand. ... Chilblain lupus erythematosus Some people with cutaneous LE also have circulatory problems. They may have chilblains (chilblain ...
- Cutaneous Lupus Erythematosus Lupus is an autoimmune disease, which affects multiple organs and systems in the body. An individual's own immune system attacks various cells causing a wide variety of signs and symptoms.
- cutaneous lupus erythematosus
- lupus erythematosus